Skip to content

Vor Biopharma VOR Free cash flow yield

Free cash flow yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3%-2.1pp
Amgen logo
AmgenAMGN
4.5%-2.0pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.3%+2.2pp
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-7%+0.3pp
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-8.2%-3.2pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-20.5%-5.1pp

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,594%
Enterprise value$617.68M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

Based on trailing twelve months.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's free cash flow yield?
Vor Biopharma (VOR) reported free cash flow yield of -17.3% in Q1 2026.
How has Vor Biopharma's free cash flow yield changed year-over-year?
Vor Biopharma's free cash flow yield increased by 84.6% year-over-year, from -112.3% to -17.3%.
What is the long-term trend for Vor Biopharma's free cash flow yield?
Over 4 years (2021 to 2025), Vor Biopharma's free cash flow yield has grown at a 31.3% compound annual growth rate (CAGR), from -16.9% to -50.1%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.